Case-control study of the risk factors for acquisition of Pseudomonas and Proteus species during tigecycline therapy

Antimicrob Agents Chemother. 2015 Sep;59(9):5830-3. doi: 10.1128/AAC.04865-14. Epub 2015 Jun 22.

Abstract

Tigecycline is an important agent in clinical practice because of its broad-spectrum activity. However, it has no activity against Pseudomonas or Proteus species. We conducted a case-control study to analyze risk factors for the acquisition of Pseudomonas or Proteus spp. during tigecycline therapy. Placement of suction drainage at infected wound sites, ICU stay, and neurologic disease were identified as independent risk factors for the acquisition of Pseudomonas and Proteus spp.

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use*
  • Case-Control Studies
  • Cross Infection / drug therapy
  • Drug Resistance, Multiple, Bacterial
  • Female
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Minocycline / analogs & derivatives*
  • Minocycline / therapeutic use
  • Proteus / drug effects
  • Proteus / pathogenicity*
  • Pseudomonas / drug effects
  • Pseudomonas / pathogenicity*
  • Retrospective Studies
  • Risk Factors
  • Tigecycline

Substances

  • Anti-Bacterial Agents
  • Tigecycline
  • Minocycline